Patents by Inventor Mark Thomas McHale

Mark Thomas McHale has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cancer therapy
    Patent number: 11382903
    Abstract: A method of treating haematological cancer with a therapy comprising a DHODH inhibitor. Also provided is a combination therapy comprising a pan-HER inhibitor and a DHODH inhibitor for treating a haematological cancer.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: July 12, 2022
    Assignee: Aslan Pharmaceuticals Pte. Ltd.
    Inventors: Bertil Lindmark, Ann Gee Lisa Ooi, Mark Thomas McHale
  • Cancer therapy
    Patent number: 11311548
    Abstract: A method of treating haematological cancer with a therapy comprising a DHODH inhibitor. Also provided is a combination therapy comprising a pan-HER inhibitor and a DHODH inhibitor for treating a haematological cancer.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: April 26, 2022
    Assignee: Aslan Pharmaceuticals Pte. Ltd.
    Inventors: Bertil Lindmark, Ann Gee Lisa Ooi, Mark Thomas McHale
  • Treatment of Biliary Duct Cancer
    Publication number: 20190117655
    Abstract: The present disclosure provides a method of treating a biliary duct cancer, such as cholangiocarcinoma, by administering a therapeutically effective amount of a compound of formula (I), in particular Varlitinib, an enantiomer thereof or a pharmaceutically acceptable salt of any one of the same.
    Type: Application
    Filed: September 18, 2018
    Publication date: April 25, 2019
    Applicant: ASLAN Pharmaceuticals PTE LTD
    Inventors: Bertil Lindmark, Mark Thomas McHale, Lisa Ooi
  • Treatment of Biliary Duct Cancer
    Publication number: 20180353510
    Abstract: The present disclosure provides a method of treating a biliary duct cancer, such as cholangiocarcinoma, by administering a therapeutically effective amount of a compound of formula (I), in particular Varlitinib, an enantiomer thereof or a pharmaceutically acceptable salt of any one of the same.
    Type: Application
    Filed: September 5, 2016
    Publication date: December 13, 2018
    Inventors: Bertil Lindmark, Mark Thomas McHale, Lisa Ooi